Format

Send to

Choose Destination
See comment in PubMed Commons below
Arthritis Res Ther. 2006;8(5):111.

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al.

Author information

1
Epidemiology Unit, University of Manchester Medical School, Manchester, UK. will.dixon@manchester.ac.uk

Abstract

A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results.

PMID:
16911768
PMCID:
PMC1779433
DOI:
10.1186/ar2026
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center